{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:21:11Z","timestamp":1793661671100,"version":"4.5.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Sichuan Educational Science Planning Project","award":["SCJG23A251"],"award-info":[{"award-number":["SCJG23A251"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-026-04845-2","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:05:35Z","timestamp":1776776735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of 0.01% low-dose atropine therapy for the myopia and premyopia in children: a meta-analysis and systematic review"],"prefix":"10.1186","volume":"26","author":[{"given":"Wanyao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjie","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangle","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"issue":"5","key":"4845_CR1","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","volume":"123","author":"BA Holden","year":"2016","unstructured":"Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050 [J]. Ophthalmology. 2016;123(5):1036\u201342.","journal-title":"Ophthalmology"},{"issue":"4","key":"4845_CR2","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40123-024-00887-1","volume":"13","author":"W Pan","year":"2024","unstructured":"Pan W, Lan W. The Current and Future Landscape of the Childhood Myopia Epidemic in China-A Review [J]. Ophthalmol Ther. 2024;13(4):883\u201394.","journal-title":"Ophthalmol Ther"},{"issue":"9","key":"4845_CR3","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jamaophthalmol.2022.2762","volume":"140","author":"H Choquet","year":"2022","unstructured":"Choquet H, Khawaja AP, Jiang C, et al. Association Between Myopic Refractive Error and Primary Open-Angle Glaucoma: A 2-Sample Mendelian Randomization Study [J]. JAMA Ophthalmol. 2022;140(9):864\u201371.","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"4845_CR4","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1136\/bjophthalmol-2021-320644","volume":"107","author":"YX Wang","year":"2023","unstructured":"Wang YX, Yang H, Wei CC, et al. High myopia as risk factor for the 10-year incidence of open-angle glaucoma in the Beijing Eye Study [J]. Br J Ophthalmol. 2023;107(7):935\u201340.","journal-title":"Br J Ophthalmol"},{"key":"4845_CR5","unstructured":"Chinese O G O O B O Associationm. Expert consensus on application of low-concentration atropine eye drops in the prevention and control of myopia in children and adolescents (2024) [J]. Chin J Optom Ophthalmol Vis Sci. 2024;26(9)."},{"issue":"12","key":"4845_CR6","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","volume":"113","author":"WH Chua","year":"2006","unstructured":"Chua WH, Balakrishnan V, Chan YH, et al. Atropine for the treatment of childhood myopia [J]. Ophthalmology. 2006;113(12):2285\u201391.","journal-title":"Ophthalmology"},{"issue":"2","key":"4845_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","volume":"119","author":"A Chia","year":"2012","unstructured":"Chia A, Chua WH, Cheung YB, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2) [J]. Ophthalmology. 2012;119(2):347\u201354.","journal-title":"Ophthalmology"},{"issue":"2","key":"4845_CR8","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","volume":"123","author":"A Chia","year":"2016","unstructured":"Chia A, Lu QS, Tan D. Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2: Myopia Control with Atropine 0.01% Eyedrops [J]. Ophthalmology. 2016;123(2):391\u20139.","journal-title":"Ophthalmology"},{"key":"4845_CR9","doi-asserted-by":"publisher","first-page":"1227787","DOI":"10.3389\/fphar.2023.1227787","volume":"14","author":"P Hou","year":"2023","unstructured":"Hou P, Wu D, Nie Y, et al. Comparison of the efficacy and safety of different doses of atropine for myopic control in children: a meta-analysis [J]. Front Pharmacol. 2023;14:1227787.","journal-title":"Front Pharmacol"},{"key":"4845_CR10","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, Mckenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews [J]. Int J Surg. 2021;88:105906.","journal-title":"Int J Surg"},{"issue":"4","key":"4845_CR11","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/APO.0000000000000609","volume":"12","author":"A Chia","year":"2023","unstructured":"Chia A, Ngo C, Choudry N, et al. Atropine Ophthalmic Solution to Reduce Myopia Progression in Pediatric Subjects: The Randomized, Double-Blind Multicenter Phase II Apple Study [J]. Asia Pac J Ophthalmol (Phila). 2023;12(4):370\u20136.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"4845_CR12","doi-asserted-by":"crossref","unstructured":"Hansen NC, Hvid-Hansen A, Moller F, et al. Two-year results of 0.01% atropine eye drops and 0.1% loading dose for myopia progression reduction in danish children: a placebo-controlled, randomized clinical trial [J]. J Pers Med. 2024;14(2).","DOI":"10.3390\/jpm14020175"},{"issue":"3","key":"4845_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10384-021-00822-y","volume":"65","author":"O Hieda","year":"2021","unstructured":"Hieda O, Hiraoka T, Fujikado T, et al. Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study [J]. Jpn J Ophthalmol. 2021;65(3):315\u201325.","journal-title":"Jpn J Ophthalmol"},{"key":"4845_CR14","doi-asserted-by":"crossref","unstructured":"Hvid-Hansen A, Jacobsen N, Moller F, et al. Myopia control with low-dose atropine in European children: six-month results from a randomized, double-masked, placebo-controlled, multicenter study [J]. J Pers Med. 2023;13(2).","DOI":"10.3390\/jpm13020325"},{"issue":"1","key":"4845_CR15","doi-asserted-by":"publisher","first-page":"238","DOI":"10.4103\/ijo.IJO_1462_21","volume":"70","author":"J Jethani","year":"2022","unstructured":"Jethani J. Efficacy of low-concentration atropine (0.01%) eye drops for prevention of axial myopic progression in premyopes [J]. Indian J Ophthalmol. 2022;70(1):238\u201340.","journal-title":"Indian J Ophthalmol"},{"issue":"9","key":"4845_CR16","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/ceo.14148","volume":"50","author":"SS Lee","year":"2022","unstructured":"Lee SS, Lingham G, Blaszkowska M, et al. Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: A randomised clinical trial [J]. Clin Exp Ophthalmol. 2022;50(9):1001\u201312.","journal-title":"Clin Exp Ophthalmol"},{"issue":"7","key":"4845_CR17","first-page":"e88047","volume":"17","author":"S Parida","year":"2025","unstructured":"Parida S, Das M, Dash S, et al. Effect of Low-Dose Atropine on Choroidal Thickness in Children With Myopia Progression [J]. Cureus. 2025;17(7):e88047.","journal-title":"Cureus"},{"issue":"8","key":"4845_CR18","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaophthalmol.2023.2855","volume":"141","author":"MX Repka","year":"2023","unstructured":"Repka MX, Weise KK, Chandler DL, et al. Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical Trial [J]. JAMA Ophthalmol. 2023;141(8):756\u201365.","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"4845_CR19","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1080\/02713683.2022.2162925","volume":"48","author":"I Sharma","year":"2023","unstructured":"Sharma I, Das GK, Rohatgi J, et al. Low Dose Atropine in Preventing the Progression of Childhood Myopia: A Randomised Controlled Trial [J]. Curr Eye Res. 2023;48(4):402\u20137.","journal-title":"Curr Eye Res"},{"key":"4845_CR20","unstructured":"J W, Z L, J D. Effects of different prevention and control methods on SFCT change in myopic children. J Chin J Strabismus Pediatr Ophthalmol [J]. 2023;31(03):30\u20133."},{"issue":"11","key":"4845_CR21","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2020.3820","volume":"138","author":"S Wei","year":"2020","unstructured":"Wei S, Li SM, An W, et al. Safety and Efficacy of Low-Dose Atropine Eyedrops for the Treatment of Myopia Progression in Chinese Children: A Randomized Clinical Trial [J]. JAMA Ophthalmol. 2020;138(11):1178\u201384.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"4845_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","volume":"126","author":"JC Yam","year":"2019","unstructured":"Yam JC, Jiang Y, Tang SM, et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control [J]. Ophthalmology. 2019;126(1):113\u201324.","journal-title":"Ophthalmology"},{"key":"4845_CR23","unstructured":"Higgins Jpt TJ, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). [J]. Cochrane; 2024."},{"issue":"6","key":"4845_CR24","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1001\/jama.2022.24162","volume":"329","author":"JC Yam","year":"2023","unstructured":"Yam JC, Zhang XJ, Zhang Y, et al. Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial [J]. JAMA. 2023;329(6):472\u201381.","journal-title":"JAMA"},{"issue":"10","key":"4845_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1167\/iovs.62.10.36","volume":"62","author":"LA Jones-Jordan","year":"2021","unstructured":"Jones-Jordan LA, Sinnott LT, Chu RH, et al. Myopia Progression as a Function of Sex, Age, and Ethnicity [J]. Invest Ophthalmol Vis Sci. 2021;62(10):36.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"4845_CR26","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/OPX.0000000000002176","volume":"101","author":"NA Brennan","year":"2024","unstructured":"Brennan NA, Shamp W, Maynes E, et al. Influence of age and race on axial elongation in myopic children: A systematic review and meta-regression [J]. Optom Vis Sci. 2024;101(8):497\u2013507.","journal-title":"Optom Vis Sci"},{"key":"4845_CR27","doi-asserted-by":"crossref","unstructured":"Lee SH, Tseng BY, Wang JH, et al. Efficacy and safety of low-dose atropine on myopia prevention in premyopic children: systematic review and meta-analysis [J]. J Clin Med. 2024;13(5).","DOI":"10.3390\/jcm13051506"},{"issue":"6","key":"4845_CR28","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1001\/jamaophthalmol.2017.1091","volume":"135","author":"Q Gong","year":"2017","unstructured":"Gong Q, Janowski M, Luo M, et al. Efficacy and Adverse Effects of Atropine in Childhood Myopia: A Meta-analysis [J]. JAMA Ophthalmol. 2017;135(6):624\u201330.","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"4845_CR29","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jamaophthalmol.2023.2097","volume":"141","author":"K Zadnik","year":"2023","unstructured":"Zadnik K, Schulman E, Flitcroft I, et al. Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial [J]. JAMA Ophthalmol. 2023;141(10):990\u20139.","journal-title":"JAMA Ophthalmol"},{"key":"4845_CR30","unstructured":"L Z ZZ. Y F, The effect of low concentration atropine eye drops on retinal and choroidal thickness and microcirculation in myopic children and adolescents %J Rec Adv Ophthalmol [J]. 2023;43(11):887\u201392."},{"issue":"6","key":"4845_CR31","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s10792-021-01755-8","volume":"41","author":"L Joachimsen","year":"2021","unstructured":"Joachimsen L, Farassat N, Bleul T, et al. Side effects of topical atropine 0.05% compared to 0.01% for myopia control in German school children: a pilot study [J]. Int Ophthalmol. 2021;41(6):2001\u20138.","journal-title":"Int Ophthalmol"},{"issue":"3","key":"4845_CR32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1089\/jop.1999.15.257","volume":"15","author":"EJ German","year":"1999","unstructured":"German EJ, Wood D, Hurst MA. Ocular effects of antimuscarinic compounds: is clinical effect determined by binding affinity for muscarinic receptors or melanin pigment? [J]. J Ocul Pharmacol Ther. 1999;15(3):257\u201369.","journal-title":"J Ocul Pharmacol Ther"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-04845-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04845-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04845-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:54:02Z","timestamp":1780448042000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-04845-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4845"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-04845-2","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"305"}}